Radiation Therapy + Fluorouracil for Rectal Cancer
Trial Summary
What is the purpose of this trial?
This trial tests if combining radiation therapy with chemotherapy can shrink tumors in patients with stage II or III rectal cancer. The treatment aims to make tumors smaller and easier to remove while protecting normal cells. The study will also look at the timing of treatments and their effects on surgery and recovery.
Research Team
Julio Garcia-Aguilar, MD, PhD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Eligibility Criteria
This trial is for adults with stage II or III rectal cancer, who can perform daily activities on their own or need some help (ECOG 0-1). They must have a tumor within 12 cm of the anal verge and no history of certain diseases like inflammatory bowel disease, familial adenomatous polyposis, or recent heart issues. Prior pelvic radiation treatments disqualify them. Adequate organ function and agreement to use birth control are required.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Conventional Surgery (Procedure)
- Fluorouracil (Anti-metabolites)
- Leucovorin Calcium (Folate Analog)
- Oxaliplatin (Platinum-based Chemotherapy)
- Radiation Therapy (Radiation Therapy)
Fluorouracil is already approved in Canada for the following indications:
- Colorectal cancer
- Breast cancer
- Stomach cancer
- Pancreatic cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Lisa M. DeAngelis
Memorial Sloan Kettering Cancer Center
Chief Medical Officer since 2021
MD from Columbia University
Selwyn M. Vickers
Memorial Sloan Kettering Cancer Center
Chief Executive Officer since 2022
MD from Johns Hopkins University
National Cancer Institute (NCI)
Collaborator
Dr. Douglas R. Lowy
National Cancer Institute (NCI)
Chief Executive Officer since 2023
MD from New York University School of Medicine
Dr. Monica Bertagnolli
National Cancer Institute (NCI)
Chief Medical Officer since 2022
MD from Harvard Medical School